

**IPAR**



**Public Assessment Report for a  
Medicinal Product for Human Use**

---

Scientific Discussion

Atorvastatin Pinewood 80 mg film-coated tablets  
Atorvastatin Calcium Trihydrate  
PA0281/218/004

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

**CONTENTS**

I. INTRODUCTION

II. QUALITY ASPECTS

III. NON-CLINICAL ASPECTS

IV. CLINICAL ASPECTS

V. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

VI. REVISION DATE

VII. UPDATE

## I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the HPRA has granted a marketing authorisation for Atorvastatin Pinewood 10, 20, 40, 80 mg film-coated tablets, from Pinewood Laboratories on 16th September 2022.

### Hypercholesterolaemia

Atorvastatin Pinewood is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.

Atorvastatin Pinewood is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.

### Prevention of cardiovascular disease

Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.

The legal basis for this submission in IE is article 10.1 of directive 2001/83/EC as amended.

The originator product is Sortis film-coated tablet by PFIZER PHARMA PFE GmbH, registered since 1996-11-01.

This product is subject to prescription which may be renewed (B), supply is through pharmacies only with advertising allowed to HCPs.

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website.

Name of the products	Atorvastatin Pinewood 10 mg film-coated tablets Atorvastatin Pinewood 20 mg film-coated tablets Atorvastatin Pinewood 40 mg film-coated tablets Atorvastatin Pinewood 80 mg film-coated tablets
Name(s) of the active substance(s) (INN)	Atorvastatin
Pharmacotherapeutic classification (ATC code)	Atorvastatin C10AA05
Pharmaceutical form and strength(s)	Film-coated tablet, 10, 20, 40, 80 mg
Marketing Authorisation Number(s) in Ireland (PA)	PA0281/218/001-004
Marketing Authorisation Holder	Pinewood Laboratories Ltd
MRP/DCP No.	CRN009T5Y

## II. QUALITY ASPECTS

### II.1. Introduction

This application is for Atorvastatin Pinewood 10, 20, 40, 80 mg film-coated tablets.

### II.2 Drug substance

The active substance is atorvastatin, present as atorvastatin calcium trihydrate, it is an established active substance described in the European Pharmacopoeia and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

The active substance specification is considered adequate to control its quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

### II.3 Medicinal product

#### P.1 Composition

Each film-coated tablet contains atorvastatin calcium trihydrate, corresponding to 10 mg, 20 mg, 40 mg or 80 mg of atorvastatin depending on the strength indicated.

The excipients in each of the medicinal products are listed in section 6.1 of the SmPC.

A visual description for each of the products is included in section 3 of the SmPC.

## P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

## P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of GMP at suitably qualified manufacturing sites.

The manufacturing process has been validated for certain aspects according to relevant European/ICH guidelines. Any outstanding validation will be appropriately conducted in line with these guidelines.

## P.4 Control of Other Substances (Excipients)

All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer's specifications.

## P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for the dosage form, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production sites have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

## P.6 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur./EU legislation for use with foodstuffs requirements.

## P.7 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

## II.4 Discussion on Chemical, Pharmaceutical and Biological Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Atorvastatin Pinewood 10, 20, 40, 80 mg film-coated tablets.

## III. NON-CLINICAL ASPECTS

### III.1 Introduction

This active substance is a generic formulation of Lipitor 10 mg, 20mg, 40mg & 80mg film-coated tablets on the European market. No new preclinical data have been submitted. As such, no pre-clinical assessment has been made on the application. This is acceptable for this type of application.

### III.2 Pharmacology

N/A

### III.3 Pharmacokinetics

N/A

### III.4 Toxicology

N/A

### III.5 Ecotoxicity/environmental risk assessment

Since Atorvastatin Pinewood 10 mg, 20 mg, 40 mg and 80 mg film-coated tablets are generic products, they will not lead to an increased exposure to the environment. Additional studies on environmental risk assessment are therefore not deemed necessary.

### III.6 Discussion on the non-clinical aspects

Pharmacodynamic, pharmacokinetic and toxicological properties of atorvastatin calcium trihydrate are well known. As atorvastatin calcium trihydrate is a widely used, well-known active substance, the applicant has not provided additional nonclinical studies and further studies are not required. A nonclinical overview based on literature review was provided and is acceptable for this type of generic application. Non-clinical findings are adequately represented in the appropriate sections of the SmPC.

## IV. CLINICAL ASPECTS

### IV.1 Introduction

**ATC Code: C10AA05**

**Pharmacotherapeutic group: HMG-CoA reductase inhibitors (statins)**

Atorvastatin is a synthetic HMG-CoA reductase inhibitor (Statin).

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols including cholesterol. It also has a secondary effect of reducing triglyceride levels.

Atorvastatin reduces levels of cholesterol and lipoproteins in plasma by inhibiting of HMG-CoA reductase and by inhibiting the synthesis of cholesterol in the liver, and it increases a number of hepatic LDL receptors on the cellular surface, accelerating the absorption and catabolism of LDL. Atorvastatin reduces the production of LDL and a number of LDL particles. It also decreases LDL-cholesterol levels in patients with homozygous familial hypercholesterolemia.

It has been demonstrated that reduction of total cholesterol, LDL-cholesterol and triglycerides decreases the risk of cardiovascular morbidity and cardiovascular mortality.

Atorvastatin is currently approved as an adjunct to diet for reduction of elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides in patients with primary hypercholesterolemia (including heterozygous, familial hypercholesterolemia) or mixed hyperlipidaemia, when response to diet and other non-pharmacological measures are inadequate. Atorvastatin is also indicated to reduce total- or LDL-cholesterol in patients suffering from homozygous familial hypercholesterolemia, either combined with procedures such as aphaeresis and in the absence of the availability of such treatments. Furthermore, Atorvastatin is indicated as primary prevention of cardiovascular events. Approved doses include 10, 20, 40 and 80mg once daily, independent of meals. The patient should be placed on a standard cholesterol-lowering diet before receiving a statin and should continue on this diet during treatment. The dose should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response.

The usual starting dose is 10 mg once a day. Adjustment of dose should be made at intervals of 4 weeks or more. The maximum dose is 80 mg once a day.

### Therapeutic indications of the reference product

#### Hypercholesterolaemia

Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.

Atorvastatin is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.

#### Prevention of cardiovascular disease

Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.

### Posology and method of administration

#### Posology

The patient should be placed on a standard cholesterol-lowering diet before receiving Atorvastatin and should continue on this diet during treatment with Atorvastatin.

The dose should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response.

Starting dose is 10 mg once a day. Adjustment of dose should be made at intervals of 4 weeks or more.

The maximum dose is 80 mg once a day.

#### **Co-administration with other medicines**

In patients taking hepatitis C antiviral agents elbasvir/grazoprevir concomitantly with atorvastatin, the dose of atorvastatin should not exceed 20 mg/day (see sections 4.4 and 4.5).

#### **Primary hypercholesterolaemia and combined (mixed) hyperlipidaemia**

The majority of patients are controlled with Atorvastatin 10 mg once a day. A therapeutic response is evident within 2 weeks, and the maximum therapeutic response is usually achieved within 4 weeks. The response is maintained during chronic therapy.

#### **Heterozygous familial hypercholesterolaemia**

Patients should be started with Atorvastatin 10 mg daily. Doses should be individualised and adjusted every 4 weeks to 40 mg daily. Thereafter, either the dose may be increased to a maximum of 80 mg daily or a bile acid sequestrant may be combined with 40 mg atorvastatin once daily.

#### **Homozygous familial hypercholesterolaemia**

Only limited data are available (see section 5.1).

The dose of atorvastatin in patients with homozygous familial hypercholesterolemia is 10 to 80 mg daily (see section 5.1). Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable.

#### **Prevention of cardiovascular disease**

In the primary prevention trials the dose was 10 mg/day. Higher doses may be necessary in order to attain (LDL-) cholesterol levels according to current guidelines.

#### **Renal impairment**

No adjustment of dose is required (see section 4.4).

#### **Hepatic impairment**

Atorvastatin should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2). Atorvastatin is contraindicated in patients with active liver disease (see section 4.3).

#### **Elderly**

Efficacy and safety in patients older than 70 using recommended doses are similar to those seen in the general population.

#### **Paediatric population**

##### *Hypercholesterolaemia*

Paediatric use should only be carried out by physicians experienced in the treatment of paediatric hyperlipidaemia and patients should be re-evaluated on a regular basis to assess progress.

For patients with Heterozygous Familial Hypercholesterolemia aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day (see section 5.1). The dose may be increased to 80 mg daily, according to the response and tolerability. Doses should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of 4 weeks or more. The dose titration to 80 mg, daily is supported by study data in adults and by limited clinical data from studies in children with Heterozygous Familial Hypercholesterolemia (see sections 4.8 and 5.1).

There are limited safety and efficacy data available in children with Heterozygous Familial Hypercholesterolemia between 6 to 10 years of age derived from open-label studies. Atorvastatin is not indicated in the treatment of patients below the age of 10 years. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.

Other pharmaceutical forms/strengths may be more appropriate for this population.

**Method of administration**

Atorvastatin is for oral administration. Each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.

The applicant has conducted one bioequivalence study, at 80mg, to support this application. A biowaiver has been submitted for the 10mg, 20mg and 40mg doses.

The 'ten-year rule' applies and, in accordance with these provisions the Applicant has not conducted clinical studies in support of this application. However, a bioequivalence study has been performed to determine therapeutic equivalence and to complete the demonstration of essential similarity within the terms of article 10(2)(b) Directive 2004/27/EC.

To support the application, the applicant has submitted as one bioequivalence study. This is a comparative single-dose bioavailability study of two 80 mg atorvastatin tablet formulations in healthy volunteers under fasting conditions. The study code is OTA-2413-10.

This was a single centre, randomized, single-dose, 3-period crossover reference-replicate BA study to compare the bioavailability of the test ATORVASTATIN versus and the reference SORTIS®, under fasting conditions. For each study period, subjects were confined from at least 12 hours before the drug administration until after the 24.0-hour post-drug blood sample. Subjects were asked to return for the subsequent blood draw 36.0 and 48.0 hours post-drug administration. The treatment phases were separated by washout period of 14 days.

**Study Centres:**

**Clinical:** UNIVERSITY OF SKOPJE, MEDICAL FACULTY, Department of Preclinical and Clinical Pharmacology & Toxicology, 50 Divizija b.b., 1000 Skopje, Republic of Macedonia

**Analytical:** Anapharm Europe S.L., Encuny 11, 2nd Floor, 08038 Barcelona, Spain

**Statistical:** PharmaNet 2500, rue Einstein, Québec (Québec), Canada G1P 0A2

**Principal Investigator:**

Nikola Labacevski, MD, Ph.D.

**Sponsor:**

ALKALOID AD, SKOPJE Bul. Aleksandar Makedonski br.12m 1000 Skopje, Republic of Macedonia

**Protocol Date:** 30.10.2010

**Trial date:**

Clinical Portion: 28.12.2010 to 27.01.2011

**Test Formulation (A)/ Reference Formulation (B)****Test Product (A)**

**Formulation:** Atorvastatin (TORVEX)

**Manufactured by:** ALKALOID AD, SKOPJE, Republic of Macedonia

**Batch No.:** 30528 0710

**Manufacturing Date:** Not available

**Expiry Date:** 07.2012

**Reference Product (B):**

**Formulation:** Atorvastatin (SORTIS)

**Manufactured by:** PARKE-DAVIS GmbH/PFIZER PHARMA GmbH, Germany

**Batch No.:** 0629040D

**Expiry Date:** 03.2013

Treatment Identification:	Test (A)	Reference (B)
Product Name:	ATORVASTATIN (TORVEX <sup>®</sup> )	ATORVASTATIN (SORTIS <sup>®</sup> )
Company Responsible for Manufacturing	ALKALOID AD, SKOPJE, Republic of Macedonia	PARKE-DAVIS GmbH/PFIZER PHARMA GmbH, Germany
Batch/Lot Number	30528 0710	0629040D
Manufacturing Date	Not available	Not available
Expiration Date	07.2012	03.2013
Strength	80 mg	80 mg
Dosage Form	Film-coated tablet	Film-coated tablet
Dose Administered	1 x 80 mg	1 x 80 mg
Route of Administration	oral	oral

### Population(s) studied

A total of 45 healthy, male subjects were enrolled in this study. 44 subjects completed the study. In accordance with the study protocol, data from all subjects who completed the three study periods and for whom the pharmacokinetic profile was adequately characterized were used for pharmacokinetic and statistical analyses (N=44). Subject No. 25 was not included in the pharmacokinetic and statistical analyses since there was no available concentration in Period 3. The clinical part of the study was planned to be performed in the UNIVERSITY OF SKOPJE, MEDICAL FACULTY, Department of Preclinical and Clinical Pharmacology & Toxicology in 2010.

Table 10.1.1 Disposition of Subjects

Volunteers that signed study-specific ICF and were randomized:	N=45	
Safety population:	N=45	
	Treatment A	Treatment B
Dosed in Period 1:	N=15	N=30
Not dosed:	N=0	N=0
Completed:	N=15	N=30
Dosed in Period 2:	N=15	N=30
Not dosed:	N=0	N=0
Completed:	N=15	N=30
Dosed in Period 3:	N=15	N=29
Not dosed:	N=0	N=1
Completed:	N=15	N=29
Completed all treatment periods:	N=44	
PK population:	N=44	

A= ALKALOID AD, SKOPJE, Republic of Macedonia, atorvastatin 1 x 80 mg tablet.

B= PARKE-DAVIS GmbH/PFIZER PHARMA GmbH, Germany (SORTIS<sup>®</sup>), atorvastatin 1 x 80 mg tablet.

For each study period, subjects were confined from at least 12 hours before the drug administration until after the 24.0-hour post-drug blood sample. Subjects were asked to return for the subsequent blood draw 36.0 and 48.0 hours post-drug administration. Confinement was required for strict control of adherence to protocol and to guarantee the volunteers' safety. The treatment phases were separated by washout period of 14 days.



Randomization of the test and the reference dosage form administration over the subject and the study session was performed using the random number generator. Subjects were randomly assigned to one of the following sequences: ABB, BAB, or BBA. The randomization scheme was generated by PharmaNet.

At approximately 12 hours pre-dose, standard meals (with a non-carbonated, non-xanthines and nongrapefruit containing beverage) was provided to the trial subjects. Meals were identical for all periods.

Fluid intake was controlled and consistent as follows:

- Water was restricted from 1 hour pre-dose until 1 hour post dose. Water was provided ad libitum at all other times.
- At 5 and 10 hours post-dose, standard meals (with a non-carbonated, non-xanthines and nongrapefruit containing beverage) were provided to trial subjects

Trials subjects were requested:

- To avoid consumption of any grapefruits or any grapefruit-containing beverages and food for 10 days before the first dosing and throughout the study (including washout periods) until the last blood sample was collected;
- To abstain from any alcohol consumption from 3 days before each dose until collection of the final sample for that period;
- To avoid consumption of any xanthines containing beverages and food (coffee, tea, cocoa, chocolate, and cola) and carbonated drinks for the last 24 hours before each dosing and throughout the period of sample collection.
- An alcohol breath test, a urine cotinine test, and a urine drug screen were performed before dosing of each period. If there is any doubt about alcohol use at admission, the Investigator may have performed a test for alcohol.

After an overnight fast of at least 10 hours, subjects were dosed on the mornings of December 28, 2010, January 11, 2011, and January 25, 2011, around 07:30. Subjects were administered the test or reference medication (as per the randomization scheme) as a single oral dose of one film-coated tablet containing 80 mg of atorvastatin, with 240 mL of water at room temperature. The tablet must have been swallowed as a whole and must not have been chewed or broken. A check of each subject's mouth was performed to ensure drug ingestion.

Blood samples for pharmacokinetic analysis were collected according to the following scheduled: 0 (pre-drug administration) and at 0.167, 0.333, 0.500, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.0, 12.0, 24.0, 36.0, and 48.0 hours post-dose in each period. Blood samples were centrifuged at a temperature of 4°C (nominal; approximately 3000 rpm [about 1900 g]) for 10 minutes within 80 minutes after blood collection. Obtained plasma was divided in two aliquots and stored into polypropylene tubes. The aliquots were capped and store frozen at  $-85 \pm 15^{\circ}\text{C}$  until assayed. Throughout sample collection and following centrifugation, the samples were maintained in an ice bath until stored in the freezer. All frozen samples were be delivered on sufficient dry ice to keep the samples frozen using data logger in two separate shipments to the analytical facility Anapharm Europe S.L. The second aliquots were sent to the Sponsor.

### **Biowaiver**

A bioequivalence study was carried out comparing the test product Atorvastatin Torvex 80mg to Atorvastatin Sortis 80mg of PFIZER PHARMA PFE GmbH, Germany.

Based on acceptable bioequivalence studies for Atorvastatin 80 mg film-coated tablet, a biowaiver is requested for Atorvastatin 10 mg, 20mg and 40mg film coated tablets according to the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1/Corr). The applicant's justification for the bio-waiver is provided below.

1. Atorvastatin 10 mg, 20 mg, 40 mg film-coated tablets are manufactured by the same manufacturer and using the same manufacturing process.
2. The qualitative composition of atorvastatin 10 mg, 20 mg, 40 mg film-coated tablets is the same as that of atorvastatin 80 mg film-coated tablets.
3. Atorvastatin 10 mg, 20 mg, 40 mg film-coated tablets are dose proportional with atorvastatin 80 mg film-coated tablets. Thus, the ratio of amount of active substance and the excipients is the same for all the strengths.
4. The dissolution profile of Atorvastatin 10 mg, 20 mg, 40 mg film-coated tablets is similar to atorvastatin 80 mg film-coated tablets

Dissolution profiles of Atorvastatin 80mg film-coated tablets were attained in three different mediums: buffer pH 2.2, buffer pH 4.5 and buffer pH 6.8.

Comparative dissolution profiles for the test vs reference, respectively, were attained for 80mg vs 80mg, 10mg vs 80mg, 10mg vs 10mg, 20mg vs 80mg, 20mg vs 20mg, 40mg vs 80mg and 40mg vs 40mg.

**GCP aspects**

Study Code: OTA-2413-10 (Project No. 100283) Atorvastatin 80 mg Tablet. A statement is provided declaring that all clinical work was conducted according to all stipulations of the study protocol, especially the Note for Guidance on Good Clinical Practices (GCP; CPMP/ICH/133/96, January 1997), Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98, January 2001), EU Good Manufacturing Practices (GMP, Annex 13 Rev 1 July 2003) last revision of Declaration of Helsinki, and all confidentiality statements.

The study, carried out outside the European Union, met the ethical requirements of Directive 2001/20/EC.

Clinical Facility	Clinical Laboratory Facility	Scientific and Regulatory Affairs Facility	Bioanalytical Facility
UNIVERSITY OF SKOPJE, MEDICAL FACULTY, Department of Preclinical and Clinical Pharmacology & Toxicology, 50 Divizija b.b., 1000 Skopje, Republic of Macedonia	adrialab <sup>®</sup> -synlab laboratory, Drenak 6, 1000 Skopje, Republic of Macedonia	PharmaNet 2500, rue Einstein Québec (Québec), Canada, G1P 0A2	Anapharm Europe S.L., Encuny 11, 2 <sup>nd</sup> Floor, 08038 Barcelona, Spain

**IV.2 Pharmacokinetics****Pharmacokinetic properties****Absorption**

Atorvastatin is rapidly absorbed after oral administration, maximum plasma concentrations (C<sub>max</sub>) occur within 1 to 2 hours. The low absolute bioavailability of atorvastatin parent drug of approximately 12% -14% is due to presystemic clearance in the gastrointestinal mucosa and/or firstpass metabolism in the liver, its primary site of action. The systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. Although food decreases rate and extent (C<sub>max</sub>, AUC) of drug absorption by approximately 25.2% and 8.6% respectively, LDL-C reduction is similar whether atorvastatin is given with or without food. Following evening drug administration atorvastatin plasma concentrations are 30% lower for C<sub>max</sub> and AUC when compared with morning drug administration. However, LDL-C reduction is the same regardless of the time of day of administration. Extent of absorption increases in proportion to atorvastatin dose. Dose dependent reductions in LDL cholesterol levels ranging from 41% to 61% have been reported for the dose range of 10 to 80 mg/dl. Grapefruit juice in large amounts has been shown to interfere with the metabolism of atorvastatin, causing increases in C<sub>max</sub> and AUC.

**Distribution**

Mean volume of distribution of atorvastatin is approximately 381 L, determined following administration of 5 mg as an intravenous infusion. Plasma protein binding is up to 98%.

**Metabolism**

Atorvastatin undergoes extensive hepatic and/or extra-hepatic metabolism. Atorvastatin is metabolized by cytochrome P450 3A4 to ortho (= 2-OH)- and para(= 4-OH)hydroxylated derivatives and various beta-oxidation products. Atorvastatin and its 2-OH- and 4-OH- metabolites were found to have equal inhibitory effects on HMG-CoA reductase in vitro. The active metabolites are responsible for approximately 70% of the inhibition of HMG-CoA reductase. Atorvastatin is extensively metabolized in the gut wall and liver, at least in part by the CYP3A4 enzymes. The 2-OH- and 4-OH-atorvastatin metabolites have HMG-CoA reductase inhibitory activity equal to that of Atorvastatin. Approximately 70% of atorvastatin's pharmacological activity is attributed to active metabolites. However, the 4-OH-metabolite has much lower concentrations and may not contribute significantly to the drug activity. Therefore, additional to the plasma concentrations of atorvastatin, concentrations of the active metabolite ortho-hydroxyatorvastatin (2-OH-Atorvastatin) were measured.

**Elimination**

T<sub>1/2β</sub> is approximately 14 hours however due to the contribution of active metabolites the inhibitory activity for HMG-CoA reductase is approximately 20 – 30 hours.

**Drug-Drug interactions and drugs whose pharmacokinetics are influenced by atorvastatin**

Theoretically, all drugs that are inhibitors of CYP3A4 isoenzyme have the potential to increase atorvastatin plasma concentrations during their concomitant use.

SmPC Section 4.5, Table 1 and Table 2 adequately cover potential interactions and provides clinical recommendations to mitigate/minimize toxicity.

The clinical overview on the clinical pharmacology, efficacy and safety is adequate.

### IV.3 Pharmacodynamics

Atorvastatin is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which is used for the treatment of hypercholesterolemia. HMG-CoA reductase is the rate-limiting enzyme in de novo cholesterol synthesis. HMG-CoA reductase inhibitors appear to reduce the production of mevalonic acid from HMG-CoA, resulting in a reduction in hepatic cholesterol synthesis. This in turn results in a compensatory increase in the expression of high affinity low-density lipoprotein (LDL) receptors on hepatocyte membranes and stimulation of LDL catabolism. It is in this manner that atorvastatin produces the lowering of plasma total and LDL cholesterol levels observed in patients with hypercholesterolemia. Reductions in the hepatic pool of cholesterol have also been associated with a decrease in the rate of production of very-low-density lipoprotein (VLDL) and/or LDL by the liver.

Atorvastatin reduces total-C, LDL-C, VLDL-C, Apo B, and TG, and increases HDL-C in patients with hypercholesterolemia and mixed dyslipidemia. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy

### IV.4 Clinical Efficacy

No new clinical trials were submitted as part of this application.

### IV.5 Clinical Safety

No new clinical trials were submitted as part of this application.

#### Risk Management Plan

The applicant has submitted a risk management plan (RMP) in accordance with the requirements of Directive 2001/83/EC as amended describing the pharmacovigilance activities, and interventions designed to identify, characterise, prevent or minimise risks relating to Atorvastatin Pinewood 10, 20, 40 and 80 mg film coated tablets. The RMP (version 1.0; date 20/07/2021) is acceptable. The approved summary of safety concerns is outlined in the table below:

Summary of Safety Concerns	
Important identified risks	Hepatotoxicity Skeletal muscle effects, rhabdomyolysis, and rhabdomyolysis related events Hyperglycaemia, which may require diabetes care in patients Steven-Johnson syndrome and toxic epidermal necrolysis Interstitial lung disease Concomitant use of coumarin anticoagulants / warfarin
Important potential risks	Haemorrhagic stroke Autoimmune events
Missing information	Use in paediatric patients < 10 years of age

Routine risk minimisation measures and routine pharmacovigilance activities are proposed to address the safety concerns outlined above and this is considered acceptable.

The Applicant should submit Periodic Safety Update Reports (PSUR) Periodic Safety Update Reports (PSUR) in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

### IV.6 Discussion on the clinical aspects

This application contains a review of published clinical data and bioequivalence has been shown between the test product Atorvastatin 80mg film coated tablet and the reference product Atorvastatin (SORTIS) 80mg film coated tablet.

## V. OVERALL CONCLUSIONS

In general, it is widely accepted that the benefit risk of Atorvastatin is positive.

Safety issues arise mostly due to drug-drug interactions and these risks are detailed in the SmPC.

From a clinical and quality perspective the overall assessment outcome of Atorvastatin Pinewood 10, 20, 40, 80 mg film-coated tablets is positive.

Bioequivalence has been shown to be in compliance with the CHMP guidance documents. The SmPC is consistent with that of the reference product.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

*For applications under Article 8(3), 10a, 10b all following statements can be used:*

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

**VI. REVISION DATE**

5 years from the finalisation of the procedure.

**VII. UPDATES**

This section reflects the significant changes following finalisation of the initial procedure.

SCOPE	PROCEDURE NUMBER	PRODUCT INFORMATION AFFECTED	DATE OF START OF PROCEDURE	DATE OF END OF PROCEDURE